EDAP TMS S.A. (EDAP)
| Market Cap | 185.94M |
| Revenue (ttm) | 60.13M |
| Net Income (ttm) | -22.62M |
| Shares Out | 36.91M |
| EPS (ttm) | -0.64 |
| PE Ratio | n/a |
| Forward PE | 38.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 62,469 |
| Open | 5.33 |
| Previous Close | 5.40 |
| Day's Range | 4.95 - 5.34 |
| 52-Week Range | 3.60 - 12.65 |
| Beta | 1.05 |
| Analysts | Strong Buy |
| Price Target | 13.75 (+165.96%) |
| Earnings Date | Nov 9, 2023 |
About EDAP
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological an... [Read more]
Analyst Forecast
According to 4 analysts, the average rating for EDAP stock is "Strong Buy." The 12-month stock price forecast is $13.75, which is an increase of 165.96% from the latest price.
News
EDAP Appoints Lance Willsey, M.S., M.D. to Board of Directors
LYON, France, December 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Lance Willsey, M.S., M.D...
EDAP Receives 2023 Industry Category Award from the French National Institute for Intellectual Property (INPI) for Its Therapeutic Ultrasound Technology
LYON, France, November 30, 2023 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, today announced that is has received the Industry Category Award from the F...
EDAP to Present at Piper Sandler's 35th Annual Healthcare Conference
LYON, France, November 20, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is schedu...
EDAP Announces Third Quarter 2023 Financial Results
- Strong Q3 2023 U.S. Focal One ® HIFU procedure growth of +150% year-over-year - - Record nine months HIFU revenues reflecting growing demand - - Two additional Focal One systems already placed in th...
EDAP to Present at the Jefferies London Healthcare Conference
LYON, France, November 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is schedul...
EDAP TMS SA to Announce Third Quarter 2023 Financial Results on November 9, 2023
Company to host conference call and webcast on Thursday, November 9 th at 8:30am EDT LYON, France, October 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-b...
EDAP to Present at Morgan Stanley Annual Global Healthcare Conference and the H.C. Wainwright Annual Global Investment Conference
LYON, France, September 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is schedu...
EDAP Announces Second Quarter 2023 Financial Results
- Record second quarter and first half revenue s of EUR 14.3 million (USD 15 .5 million) and EUR 29.1 million (USD 31.5 million), respectively -
EDAP TMS SA to Announce Second Quarter 2023 Financial Results on August 24, 2023
- Company to host conference call and webcast on Thur sday, August 24 th at 8:30 am EDT -
EDAP Announces Reimbursement Approval in Switzerland for the Use of High-Intensity Focused Ultrasound (HIFU) in the Treatment of Prostate Cancer
LYON, France, July 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it has received reimbursement approval in Switzerla...
EDAP to Present at the Jefferies Healthcare Conference
LYON, France, May 24, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled t...
EDAP Announces First Quarter 2023 Financial Results
- Record first quarter revenue - - Positive results from two studies reconfirm safety and efficacy of Focal One - - Company to host conference call and webcast today, Wednesday, May 17 th at 8:30 am E...
EDAP to Announce First Quarter 2023 Financial Results on May 17, 2023
- Company to host conference call and webcast on Wednesday, May 1 7 th at 8:30 am EDT - LYON, France, May 3, 2023 - EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-base...
EDAP Announces Major Presence at Upcoming Annual Meeting of the American Urological Association (AUA)
Meeting to Showcase EDAP's Focal One ® Robotic High Intensity Focused Ultrasound (HIFU) Platform for the Management of Prostate Cancer LYON, France, April 21, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the ...
EDAP Announces Live Procedure Broadcast of Focal One High Intensity Focused Ultrasound (HIFU) to Global Clinical Audience
Leading Center Demonstrates Focal HIFU as a Tool in The Management of Prostate Cancer
EDAP Announces Regulatory Clearance of ExactVu Micro-Ultrasound in Japan
Allows for market launch of the only micro - ultrasound platform for precision prostate biopsies
EDAP Reports Record Fourth Quarter and Full-Year 2022 Results and Announces Leadership Succession Plan to Develop Global Group Strategy
LYON, France, March 30, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today unaudited financial results for the fourth quarter and fu...
EDAP Presents Positive Results from Non-Inferiority Study Comparing Outcomes of Focal One HIFU Versus Radical Prostatectomy at EAU23
Results demonstrate salvage treatment free survival rate (STFS) at 30 months of 90.1% in the HIFU-treated arm versus 86.8% in patients who underwent radical prostatectomy (RP)
EDAP to Announce Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 30th
LYON, France, March 9, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourt...
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2022 Revenue
Record f ull-year 2022 total preliminary unaudited revenue of €55.1 million ($58 .0 million) represents an increase of 25. 1 % over full-year 2021, driven by 58.1% HIFU growth
EDAP Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound (HIFU) for the Treatment of Rectal Endometriosis
Focal One ® HIFU treatment resulted in significant improvements in endometriosis symptoms and quality of life (QoL) Positive safety profile with 9 6 . 7 % of patients with no or non- significant adve...
EDAP Announces Record Q4 US Focal One Placements
Company preliminarily reports nine Focal One Placements in the U.S. , including seven sales
EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company's U.S. Subsidiary
LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in robotic energy-based therapies, announced today that the Company has hired medical capital equipment ...
EDAP Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis
LYON, France, November 30, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic therapeutic ultrasound, today announced that the Company has received approval from French a...
EDAP to Present at the Piper Sandler 34th Annual Healthcare Conference
LYON, France, November 21, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today that Marc Oczachowski, Chief Executive Officer, is sch...